MiNK Therapeutics Plunges 24.87% After William Blair Downgrade

On July 15, 2025, MiNK Therapeutics experienced a significant drop of 24.87% in pre-market trading.

MiNK Therapeutics' stock price plummeted following a downgrade by William Blair. The downgrade came after the company's shares had surged by 730% on Friday, driven by a groundbreaking case study published in Nature's Oncogene. The study detailed a complete and sustained remission in a patient, which had initially boosted investor confidence. However, the subsequent downgrade by William Blair led to a sharp decline in the stock price, erasing a large portion of the previous gains.

The downgrade by William Blair was based on valuation concerns following the company's recent rally. This move by the analyst firm highlighted the volatility and risk associated with investing in high-growth biotech stocks, particularly those with recent significant price movements. The downgrade served as a reminder to investors of the importance of careful analysis and risk management in the face of rapid stock price changes.